Hepion Pharmaceuticals to Present at NASH-TAG 2024
03 Janeiro 2024 - 7:15PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage
biopharmaceutical company focused on Artificial Intelligence
(“AI”)-driven therapeutic drug development for the treatment of
non-alcoholic steatohepatitis (“NASH”), fibrotic diseases,
hepatocellular carcinoma (“HCC”), and other chronic diseases, today
announced that an abstract highlighting its lead drug candidate,
rencofilstat, will be presented at the 2024 NASH-TAG Conference,
which is being held January 4-6, 2024, in Park City, Utah.
Presentation Details
Title: Hepatic Functional
Improvement Detected by HepQuant DuO within 120 Days of Treatment
with Rencofilstat in MASH Subjects with ≥F3 Fibrosis.
Authors: SA Harrison, P Mayo, T
Hobbs, C Zhao, C Canizares, R Foster, MP McRae, SM Helmke, and GT
Everson
Date: Saturday, January 6,
2024
A copy of the presentation materials will be
accessible on the Company’s website at www.hepionpharma.com under
“Publications” in the Pipeline section.
About Hepion Pharmaceuticals
The Company's lead drug candidate, rencofilstat,
is a potent inhibitor of cyclophilins, which are involved in many
disease processes. Rencofilstat has been shown to reduce liver
fibrosis and hepatocellular carcinoma tumor burden in experimental
disease models and is currently in Phase 2 clinical development for
the treatment of NASH. In November 2021, the U.S. Food and Drug
Administration (“FDA”) granted Fast Track designation for
rencofilstat for the treatment of NASH. That was followed in June
2022 by the FDA’s granting of Orphan Drug designation to
rencofilstat for the treatment of HCC.
Hepion has created a proprietary Artificial
Intelligence deep machine learning (“AI/ML”) platform designed to
better understand disease processes and identify patients that are
rencofilstat responders. This AI/ML has the potential to shorten
development timelines and increase the observable differences
between placebo and treatment groups. In addition, Hepion’s AI/ML
can be used to drive its ongoing NASH and HCC clinical development
programs and identify other potential therapeutic indications for
cyclophilin inhibition with rencofilstat.
For further information, please contact:
Hepion Pharmaceuticals Investor
Relations732-902-4000
Hepion Pharmaceuticals (NASDAQ:HEPA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024